Novo, a holding and investment company, agreed to invest $40m in Evosep, a biotechnology company in Odense, Denmark. "Precision medicine is set to revolutionize healthcare in the coming decade or two. And precision diagnostics is a crucial first step to getting there. The Evosep One™ was engineered for robust and fast clinical proteomics and we are now very excited to accelerate our efforts towards clinical proteomics," Ole Vorm, Evosep Founder.